 |
|
|
| |
Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084
|
| |
| |
AIDS 2022 July 29- Aug 1 Montreal
S Delany-Moretlwe, JP Hughes, P Bock, S Dadabhai, D Gadama, P Hunidzarira, S Innes, D Kalonji, J Makhema, P Mandima, C Mathew, J Mpendo, P Mukwekwerere, N Mgodi, P Nahirya Ntege, C Nakabiito, H Nuwagaba-Biribonwoha, R Panchia, F Angira, N Singh, B Siziba, E Spooner, J Farrior, S Rose, R Berhanu, Y Agyei, SH Eshleman, M Marzinke, E Piwowar-Manning, S Beigel-Orme, S Hosek, A Adeyeye, J Rooney, A Rinehart, B Hanscom, M Cohen, M Hosseinipour
on behalf of the HPTN 084 study team
|
| |
|
|
|
|
|
